Methods related to bevacizumab

A method of manufacturing a bevacizumab drug product, comprising:

• providing or obtaining a test glycoprotein preparation;
• acquiring at least one value for a bevacizumab parameter listed in Table 1 for the test glycoprotein preparation;
• and
• processing at least a portion of the test glycoprotein preparation as bevacizumab drug product if the at least one value for the test glycoprotein preparation meets a reference criterion shown in Table 1 for the parameter,
• thereby manufacturing a bevacizumab drug product.

A method of manufacturing a bevacizumab drug product, comprising:

• providing a host cell that is genetically engineered to express a first amino acid sequence having a sequence with at least about 85% identity to SEQ ID NO:1 (e.g., 90, 95, 98, or 100% identity to SEQ ID NO:1) and a second amino acid sequence having a sequence with at least about 85% identity to SEQ ID NO:2 (e.g., 90, 95, 98, or 100% identity to SEQ ID NO:2), wherein the expressed amino acid sequences form a recombinant antibody composition,
• culturing the host cell under conditions whereby the cell expresses the first and second amino acid sequences, wherein the expressed first and second amino acid sequences form recombinant antibodies,
• harvesting the recombinant antibodies from the host cell culture to produce an antibody preparation,
• acquiring a value for each parameter listed in Table 1 for the antibody preparation;
• and
• processing at least a portion of the antibody preparation into bevacizumab drug product if the value for each parameter listed in Table 1 for the antibody preparation meets the reference criterion shown in Table 1,
• thereby manufacturing a bevacizumab drug product.